

680 SUPPLEMENTAL TABLES

681 **Table S1. Comparison of baseline characteristics of included and excluded patients**
682 **based on disease progression at Day +120.**

| | Disease Progression ≤ Day + 120 (Excluded) N (%) | Disease Progression > Day + 120 (Included) N (%) | P |
|-------------------------------------|---|--|----------|
| Total patients | 105 | 378 | |
| Sex | | | |
| Female | 48 (46) | 185 (49) | |
| Male | 57 (54) | 193 (51) | 0.5 |
| Age | | | |
| ≤50 | 56 (53) | 231 (61) | |
| >50 | 49 (47) | 147 (39) | 0.1 |
| Diagnosis | | | |
| AML | 81 (77) | 305 (81) | |
| MDS | 24 (23) | 73 (19) | 0.4 |
| Disease Status at Transplant | | | |
| CR1 | 22 (21) | 158 (42) | <0.001 |
| CR2 | 8 (8) | 66 (17) | |
| Not CR | 75 (71) | 154 (41) | |
| Cytogenetics | | | |
| Good Risk | 4 (4) | 50 (13) | <0.001 |
| Intermediate Risk | 41 (39) | 196 (52) | |
| Poor Risk | 57 (54) | 121 (32) | |
| Unknown | 3 (3) | 11 (3) | |
| FLT3 ITD Mutation | | | |
| Yes | 23 (22) | 45 (12) | |
| No | 58 (55) | 224 (59) | 0.02 |
| N/A | 24 (23) | 109 (29) | |
| Modified ELN Classification | | | |
| Favorable | 13 (12) | 114 (30) | |
| Intermediate 1* | 10 (9) | 32 (8) | |
| Intermediate 2 | 26 (25) | 75 (20) | |
| Adverse | 47 (45) | 85 (22) | <0.001 |
| Cg normal, FLT3 ITD N/A | 6 (6) | 56 (15) | |
| Cg N/A | 3 (3) | 16 (4) | |

| | | | |
|-------------------------------------|---------|----------|------|
| Stem Cell Source | | | |
| Bone Marrow | 43 (41) | 135 (36) | |
| Peripheral Blood | 61 (58) | 242 (64) | 0.3 |
| Cord Blood | 1 (1) | 1 (0) | |
| Donor type | | | |
| Match-related donor | 39 (37) | 195 (52) | |
| Other | 66 (63) | 183 (48) | 0.01 |
| GVHD prophylaxis | | | |
| Tacrolimus/Methotrexate | 94 (90) | 335 (89) | |
| Tacrolimus/Methotrexate/Pentostatin | 11 (10) | 42 (11) | 0.8 |
| Other | 0 | 1 (0) | |

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709 **Table S2. T-lymphocyte donor chimerism and disease progression in CR1/CR2 patients**
 710 **at time of transplant.**

| % Donor T-lymphocyte Chimerism | Total N=164 | Progressed N=30 | HR at 3 yrs | 95% CI | <i>P</i> |
|---------------------------------------|--------------------|------------------------|--------------------|---------------|-----------------|
| 100 | 70 | 9 | Ref. | | |
| 96-99 | 15 | 3 | 1.7 | 0.45-6.2 | 0.4 |
| 86-95 | 34 | 5 | 1.2 | 0.4-3.7 | 0.7 |
| 76-85 | 18 | 6 | 2.9 | 1.03-8.1 | 0.04 |
| 51-75 | 12 | 3 | 2.1 | 0.6-7.8 | 0.3 |
| ≤50 | 15 | 4 | 2.1 | 0.6-6.8 | 0.2 |

711 Ref. indicates reference

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731 **Table S3. T-lymphocyte donor chimerism and disease progression in non-CR1/CR2**
 732 **patients at time of transplant.**

| % Donor T-lymphocyte Chimerism | Total N=101 | Progressed N=34 | HR at 3 yrs | 95% CI | <i>P</i> |
|---|------------------------|----------------------------|--------------------|---------------|-----------------|
| 100 | 61 | 19 | Ref. | | |
| 96-99 | 10 | 2 | 0.96 | 0.1-7.2 | 0.9 |
| 86-95 | 11 | 6 | 2.4 | 0.8-7.1 | 0.1 |
| 76-85 | 8 | 2 | 0.8 | 0.2-3.4 | 0.8 |
| 51-75 | 8 | 4 | 1.9 | 0.8-4.8 | 0.2 |
| ≤50 | 3 | 1 | 0.6 | 0.1-2.7 | 0.5 |

733 Ref. indicates reference

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751
752
753
754
755
756
757
758
759
760
761
762
763
764
765

Table S4. Rate of disease progression by 3 years post-transplant: Subset analysis by disease status at transplant and day +90 to +120 T-lymphocyte chimerism status.

| % Donor T-lymphocyte chimerism | CR1/CR2 | | | Non-CR1/CR2 | | |
|--------------------------------|---------|---------|----------|-------------|---------|----------|
| | HR | 95% CI | <i>P</i> | HR | 95% CI | <i>P</i> |
| 100 | Ref. | | | Ref. | Ref. | |
| 86-99 | 1.4 | 0.5-3.5 | .5 | 1.3 | 0.6-3.2 | .5 |
| ≤85 | 2.4 | 1.0-5.6 | .04 | 1.3 | 0.5-2.9 | .6 |

766 Ref. indicates reference.

767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788

789
790
791
792
793
794
795
796
797
798
799
800
801
802

Table S5. Risk of disease progression according to day +90 to +120 T-lymphocyte chimerism.

| | CR1/CR2 | | | Non-CR1/CR2 | | |
|-----------------|---------|----------|----------|-------------|---------|----------|
| | *HR | 95% CI | <i>P</i> | *HR | 95% CI | <i>P</i> |
| 6 months | 1.9 | 0.6-5.9 | 0.3 | 2.4 | 0.8-7.1 | 0.1 |
| 1 year | 2.3 | 1.1-5 | 0.03 | 2 | 0.8-4.9 | 0.1 |
| 2 years | 2.2 | 1.1-4.6 | 0.03 | 1.5 | 0.6-3.5 | 0.3 |
| 3 years | 2.1 | 1.02-4.3 | 0.04 | 1.3 | 0.5-2.9 | 0.6 |

803 *Hazard ratio (HR) reflects comparison of the rate of progression according to day +90 to +120
804 T-lymphocyte donor chimerism status ($\leq 85\%$ vs. $>85\%$)

805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825